Anticoagulation and Antiplatelet Agent Resumption Timing following Traumatic Brain Injury.
Korean J Neurotrauma
; 19(3): 298-306, 2023 Sep.
Article
en En
| MEDLINE
| ID: mdl-37840609
ABSTRACT
Traumatic brain injury (TBI) is a major global health concern. Due to the increase in TBI incidence and the aging population, an increasing number of patients with TBI are taking antithrombotic agents for their underlying disease. When TBI occurs in patients with these diseases, there is a conflict between the disease, which requires an antithrombotic effect, and the neurosurgeon, who must minimize intracranial hemorrhage. Nevertheless, there are no clear guidelines for the reversal or resumption of antithrombotic agents when TBI occurs in patients taking antithrombotic agents. In this review article, we intend to classify antithrombotic agents and provide information on them. We also share previous studies on the reversal and resumption of antithrombotic agents in patients with TBI to help neurosurgeons in this dilemma.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
Korean J Neurotrauma
Año:
2023
Tipo del documento:
Article